Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Milk Supplementation and Bone Health in Children

29 september 2021 uppdaterad av: Yu-ming Chen, Sun Yat-sen University

Effects of Yili Child Formula Milk on Bone Health in 4-6 Year Children: a 12-month Randomized Controlled Trial

Objectives: to examine the effects of a Yili child formula milk and regular milk on bone health and growth in young children.

Study design: cluster randomized controlled trial.

Setting: kindergartens in Hui-ning County of Gansu Province, China (north west).

Participants: >=246 apparent healthy children aged 4-6 years old.

Interventions:

(I) Yili child formula milk (QQ star formula, SCI-PRO NUTR5+6TM), 195 ml *2 /day; (II) Yili regular milk (pure milk), 195ml*2 /day; (III) Controls: about 50g/d grain foods (containing 20-30 g carbohydrates), e.g. bread.

Interventional Duration: 12 months.

Outcome measures: determined at 0, 6 and 12 months post treatments. Primary outcomes: bone density and bone mineral contents at the forearm and heel, bone biomarkers.

Secondary outcomes: (1) anthropometric indices: weight, height, waist circumference, etc.; (2) immune status.

Other measures: dietary intakes, physical activities, general information, medical information, adverse of side effects.

Data Analyses: The one-year changes and percent changes in the primary and secondary outcomes will be compared among the 3 groups.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Förväntat)

254

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Gangshu
      • Lanzhou, Gangshu, Kina, 730000
        • LanZhou University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

4 år till 6 år (Barn)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Aged between 4-6 years;
  • female and male
  • Can be enrolled into kindergarten/school as a normal child.
  • Be willing to drinking milk daily.

Exclusion Criteria:

  • Milk allergy or intolerance, did not to be used to drinking milk;
  • Had the following diseases/conditions confirmed by a hospital: serious diseases of heart, liver, kidney, brain, hematopoietic system, immunity, thyroid or cancer that need to be hospitalization for more than 1 week or take medication(s) for more than 1 month with the past two years.
  • having infectious diseases, e.g., tuberculosis, hepatitis, etc.
  • Taking vitamin D, calcium tables or nutrient package;
  • Consumed more than 3 times (>600ml) milk each week in the previous month.
  • Be not willing to provide informed consent, or have other conditions that were considered to be unsuitable for the study by the investigators.
  • Increases of body health were out of the range between 5-8 cm in the last year.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Formula Milk

Formula milk designed for young children aged over 3 years;

Dosage: 195 ml/time;

Frequence: 2 times /day;

Duration: 12 months

Brand name: Yili (QQ star formula milk);

Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;

Dosage: 195ml*2/d;

Intervention duration: 12 months

Aktiv komparator: Regular milk

Regular milk (pure milk);

Dosage: 195 ml/time;

Frequence: 2 times /day;

Duration: 12 months

Brand name: Yili;

Type: regular milk (pure milk);

Dosage: 195ml*2/d;

Intervention duration: 12 months

Övrig: Control foods

Grain foods: e.g., bread;

Dosage: 20-40 g/time;

Frequence: 2 times /day;

Duration: 12 months

Brand: N/A;

Food type: grain foods (e.g., bread);

Dosage: 20-40g * 2/d grain foods

Intervention duration: 12 months

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline bone mineral density (BMD) at 12 months
Tidsram: 0 and 12 months
BMD (g/cm2) determined by a dual energy x-ray absorptiometry (DXA) at the left forearm and heel
0 and 12 months
Change from baseline bone mineral density (BMD) at 6 months
Tidsram: 0 and 6 months
BMD (g/cm2) determined by DXA at the left forearm and heel
0 and 6 months
Change from baseline bone mineral contents (BMC) at 12 months
Tidsram: 0 and 12 months
BMC (g) determined by DXA at the left forearm and heel.
0 and 12 months
Change from baseline bone mineral contents (BMC) at 6 months
Tidsram: 0 and 6 months
BMC (g) determined by DXA at the left forearm and heel.
0 and 6 months
Change from baseline of bone-specific alkaline phosphatase at 12 months
Tidsram: 0 and 12 months
Bone turnover marker 1: Bone-specific alkaline phosphatase
0 and 12 months
Change from baseline of bone-specific alkaline phosphatase at 6 months
Tidsram: 0 and 6 months
Bone turnover marker 1: Bone-specific alkaline phosphatase
0 and 6 months
Change from baseline of osteocalcin at 12 months
Tidsram: 0 and 12 months
Bone turnover marker 2: osteocalcin
0 and 12 months
Change from baseline of osteocalcin at 6 months
Tidsram: 0 and 6 months
Bone turnover marker 2: osteocalcin
0 and 6 months
Change from baseline of C-terminal telopeptide of type I collagen at 12 months
Tidsram: 0 and 12 months
Bone turnover marker 3: C-terminal telopeptide of type I collagen
0 and 12 months
Change from baseline of C-terminal telopeptide of type I collagen at 6 months
Tidsram: 0 and 6 months
Bone turnover marker 3: C-terminal telopeptide of type I collagen
0 and 6 months
Change from baseline of tartrate resistant acid phosphatase at 12 months
Tidsram: 0 and 12 months
Bone turnover marker 4: tartrate resistant acid phosphatase
0 and 12 months
Change from baseline of tartrate resistant acid phosphatase at 6 months
Tidsram: 0 and 6 months
Bone turnover marker 4: tartrate resistant acid phosphatase
0 and 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline body weight at 12 months
Tidsram: 0 and 12 months
Anthropometric indices: body weight
0 and 12 months
Change from baseline body height at 12 months
Tidsram: 0 and 12 months
Anthropometric indices: body height
0 and 12 months
Change from baseline biomarker of body growth at 12 months
Tidsram: 0 and 12 months
Biomarker of body growth: insulin-like growth factor 1
0 and 12 months
Change from baseline immune globulin M (Ig M)at 12 months
Tidsram: 0 and 12 months
Immune status: Blood Ig M
0 and 12 months
Change from baseline immune globulin G (Ig G)at 12 months
Tidsram: 0 and 12 months
Immune status: Blood Ig G
0 and 12 months
Change from baseline immune globulin G (Ig A)at 12 months
Tidsram: 0 and 12 months
Immune status: Blood Ig A
0 and 12 months
Change from baseline whit blood cell at 12 months
Tidsram: 0 and 12 months
Immune status: whit blood cell
0 and 12 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Concentrations of blood total 25-hydroxide-vitamin D (25-OH-VD)
Tidsram: 0, 6 and 12 months
Serum 25-OH-VD
0, 6 and 12 months
Concentrations of blood parathyroid Hormone (PTH)
Tidsram: 0, 6 and 12 months
Serum PTH
0, 6 and 12 months
Nutritional status 1: Body weight
Tidsram: 0, 4, 8 and 12 months
Body weight (in kg)
0, 4, 8 and 12 months
Nutritional status 2: waist circumference
Tidsram: 0, 4, 8 and 12 months
Waist circumference (in cm)
0, 4, 8 and 12 months
Nutritional status 3: middle-arm circumference
Tidsram: 0, 4, 8 and 12 months
Middle-arm circumference (in cm)
0, 4, 8 and 12 months
Nutritional status 4: skinfold thickness
Tidsram: 0, 4, 8 and 12 months
Skinfold thickness (in mm)
0, 4, 8 and 12 months
Total consumption of milk and dairy food
Tidsram: 0, 4, 8 and 12 months
Total consumption of milk and dairy food (in ml/d)
0, 4, 8 and 12 months
Consumption of dietary energy
Tidsram: 0, 4, 8 and 12 months
Consumption of dietary energy (in kcal/d)
0, 4, 8 and 12 months
Consumption of dietary protein
Tidsram: 0, 4, 8 and 12 months
Consumption of dietary protein (in g/d)
0, 4, 8 and 12 months
Consumption of dietary calcium
Tidsram: 0, 4, 8 and 12 months
Consumption of dietary calcium (in mg/d)
0, 4, 8 and 12 months
Number of participants with treatment-related adverse events
Tidsram: 0, 4, 8 and 12 months
Adverse events : assessed by using questionnaires of medical conditions, medications related to milk intake
0, 4, 8 and 12 months
Child behaviors
Tidsram: 0 and 12 months
Child behaviours: assessed by using a Child behavior Questionnaire-- parent version. The minimum and maximum values: 26-78; higher scores mean worse outcome.
0 and 12 months
Physical activity
Tidsram: 0, 4, 8 and 12 months
Physical activity (in MET, h/week): assessed by a Child Physical Activity Questionnaire
0, 4, 8 and 12 months
Concentrations of serum calcium
Tidsram: 0, 6 and 12 months
Serum calcium (mmol/L)
0, 6 and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Yuming Chen, Ph.D., Sun Yat-sen University
  • Studiestol: Zhifu Zhao, M. Phil, Inner Mongolia Dairy Technology Research Institute Co., Ltd.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 september 2021

Primärt slutförande (Förväntat)

30 oktober 2022

Avslutad studie (Förväntat)

30 december 2022

Studieregistreringsdatum

Först inskickad

10 september 2021

Först inskickad som uppfyllde QC-kriterierna

29 september 2021

Första postat (Faktisk)

12 oktober 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 oktober 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2021

Senast verifierad

1 september 2021

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • SYSU-51000-20210723-0001

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Published data based on reasonable request.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera